Data in literature demonstrated that Notch1 and Notch3 are pro-oncogenic,33–35 and recently it has been shown that gain of Notch2 copy number is associated with poor prognosis in metastatic triple-negative breast cancer.36 In contrast, O’Neill et al.37 provided evidence that Notch2 has a marked antitumour effect in MDA-MB-231 cells, which is in line with our observations. Here, NOTCH3 is linked to triple-negative breast carcinoma.